Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases

被引：8

作者：

Tatokoro, Manabu ^{[2
]}

Fujii, Yasuhisa ^{[1
,3
]}

Kawakami, Satoru ^{[3
]}

Fukui, Naotaka ^{[2
]}

Komai, Yoshinobu ^{[3
]}

Saito, Kazutaka ^{[2
]}

Koga, Fumitaka

Morimoto, Shinji ^{[2
]}

Fukui, Iwao ^{[3
]}

Kihara, Kazunori

机构：

[1] Tokyo Med & Dent Univ, Dept Urol, Bunkyo Ku, Tokyo 1138519, Japan

[2] Tsuchiura Kyodo Gen Hosp, Dept Urol, Tsuchiura, Ibaraki, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2008年 / 15卷 / 09期

关键词：

cimetidine; COX-2; inhibitors; metastasis; renal cell carcinoma; renin-angiotensin system inhibitors;

D O I：

10.1111/j.1442-2042.2008.02102.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

We report three cases of metastatic renal cell carcinoma (RCC) in which combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor (angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor antagonist) (CCA therapy) was effective. Case 1: A 47-year-old man who had a 12-cm right renal tumor with multiple pulmonary and hepatic metastases refused cytokine therapy for economic reasons and received CCA therapy. All of the metastases showed partial remission, which continued for 12 months. Case 2: A 62-year-old man with multiple pulmonary and mediastinal lymph node metastases from clear cell RCC refractory to interferon-alpha and interleukin-2 started CCA therapy. Partial remission has been maintained for 16 months. Case 3: A 64-year-old man with pulmonary metastases from clear cell RCC discontinued interferon-alpha treatment due to its side effects after six months and received CCA therapy. Pulmonary metastases showed partial remission for 31 months. The CCA therapy could be an alternative treatment for metastatic RCC patients unfit for cytokine therapy.

引用

页码：848 / 850

页数：3

共 11 条

[1] [Anonymous], CAMPBELL WALSH UROLO
[2] The renin angiotensin system in the regulation of angiogenesis
Heffelfinger, S. C.
[J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (12) : 1215 - 1229
[3] INHORN L, 1992, AM J CLIN ONCOL-CANC, V15, P157
[4] Spontaneous regression of metastatic renal cancer - Case report and literature review
Lokich, J
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 416 - 418
[5] Miyajima A, 2002, CANCER RES, V62, P4176
[6] Nagano T, 1996, Nihon Hinyokika Gakkai Zasshi, V87, P1201
[7] Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
Rini, BI
Weinberg, V
Dunlap, S
Elchinoff, A
Yu, N
Bok, R
Simko, J
Small, EJ
[J]. CANCER, 2006, 106 (03) : 566 - 575
[8] Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment
Uemura, Hiroji
Ishiguro, Hitoshi
Kubota, Yoshinobu
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (01) : 19 - 26
[9] Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
Vogl, U. M.
Zehetgruber, H.
Dominkus, M.
Hejna, M.
Zielinski, C. C.
Haitel, A.
Schmidinger, M.
[J]. BRITISH JOURNAL OF CANCER, 2006, 95 (06) : 691 - 698
[10] HISTAMINE SUPPRESSION OF HUMAN LYMPHOCYTE-RESPONSES TO MITOGENS
WANG, SR
ZWEIMAN, B
[J]. CELLULAR IMMUNOLOGY, 1978, 36 (01) : 28 - 36

← 1 2 →